MEDDIC still qualifies, SPIN still asks, Challenger still teaches, JOLT still closes. What changes is the ground under them. In a market with references the methods stood on earlier results; in enterprise AI they stand on a few truths agreed in the room. What is new is a claim written with the buyer, signed by the buyer, that says what would prove it wrong, holds whoever wins, and lives in the buyer's own decision file.
Underneath, not instead
The Thesis-Based Selling framework replaces none of these methods. It sits underneath them.
What is new, in one table
A sales leader with twenty years in the job asks the fair question: if you have learned the customer's business, challenged their assumptions and tied a future to a purchase, what have you been doing, if not this?
Much of it, honestly. A seller who has done those things well has been running part of Thesis-Based Selling without the name, and I am not claiming to have discovered that beliefs drive decisions. What I claim is narrower, and it fits in one table.
| Idea | Who writes the claim | Does it say what would prove it wrong? | Does it hold whoever wins? | Where it lives afterward |
|---|---|---|---|---|
| Challenger insight | The vendor, from patterns across many customers | Rarely | No: it is built to lead to the vendor's strengths | The seller's deck |
| Strategic narrative | The vendor's marketing team | No | No: it ends in the vendor's product | The pitch, told to every buyer |
| Hypothesis-led discovery | The seller, about one account | Yes, and then it is thrown away | Usually | The seller's notes, for a meeting or two |
| MEDDIC decision criteria | The buyer, often copied from the last purchase | No | Yes | The CRM and the RFP |
| A thesis, in this book | The seller and the buyer together, signed by the buyer | Always, in writing | It must, or it fails the six checks | The buyer's own decision file |
Read the last row across, and you have the claim of this book. No single cell in it is new. Buyers have co-written documents before, falsifiers come from science, neutral claims come from analysts, and buying committees have always kept a file. What is new is holding all four at once, on purpose, and building the sale on the result.
Where the thesis plugs into each method
MEDDIC, and its longer form MEDDPICC, for qualification. MEDDIC is a checklist for deciding whether a deal is real: Metrics, the measurable benefit; the Economic buyer, the person who can spend the money; the Decision criteria and the Decision process the buyer will use; the pain the deal solves; and a Champion inside the buyer who will fight for it.
The thesis plugs into the D's and the M. Decision criteria only mean something once the buyer has agreed what is true: criteria written before the thesis tend to be copied from the last purchase. In AI the Metrics rarely come from earlier customers, so they come from the thesis instead: if this is true, here is what we should be able to measure.
SPIN Selling, for questions. SPIN orders the questions in discovery: Situation questions about the facts, Problem questions about difficulties, Implication questions about what those difficulties cost, and Need-payoff questions that let the buyer say what solving them would be worth. It lives in the early meetings. The thesis plugs into the last two.
The Challenger Sale, for insight. The Challenger teaches the customer something new about their own business, tailors it to each person, and takes control of the conversation. It sits in the first serious meeting. Where a market has references, teach. Where it does not, form the thesis with the buyer, as this chapter described earlier: the reframe becomes the moment you lay the thesis on the table, and taking control means keeping the room on the thesis instead of drifting back to features.
One deal, run two ways
An insurer is choosing an AI platform for its claims team. Two sellers bring the same insight and run the same MEDDIC. The first goes into the committee without having asked what the room believes about the future, and the deal goes to no decision. The second lays three theses on the table in week two and asks which the room does not buy. Legal attacks one, and ends up agreeing with it in writing.
Look at what changed and what did not. The insight was the same, and so was the qualification. A brilliant Challenger seller might have found legal's objection anyway, and some do. What the method changed is that finding it was not left to brilliance. It was a step: lay the beliefs down, ask which ones the room rejects, and write the decision on what survives.
One deal with every method in it
- Qualify. In the first week, run MEDDPICC. Is there a decision to make, an economic buyer and a reason to act this year?
- Agree inside. Before the first big meeting, run the thesis session from Chapter 8 with the person who sells beside you.
- Discover. Use SPIN. Let the Implication questions surface what the buyer believes. Map each buying influence and their premises, Strategic Selling style.
- Reframe. In the first serious meeting, lead with a Challenger insight: lay down three theses and stipulate what everyone accepts, as Chapter 9 describes.
- Build. With the buyer, build the stack, the chain from thesis to implication to decision that Chapter 9 describes. Write the Decision criteria from it. Size the gap, Gap Selling style, against the agreed future state, and shape the solution vision on it.
- Carry. Give your Champion the stack in three sentences, so it travels without you.
- Defend. Take every challenge as Chapter 10 describes, and keep the ledger.
- Decide. If the deal stalls, use JOLT: recommend from the thesis, narrow the options, and take the risk off the table with the falsifier, the agreed statement of what would prove the thesis wrong, and an early checkpoint.
The frameworks tell you how to run the sale. The thesis is what you stand on while you run it.